{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:16:39Z","timestamp":1791252999528,"version":"4.1.0"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22278270"],"award-info":[{"award-number":["22278270"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017577","name":"Basic Public Welfare Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["LGF20H300004"],"award-info":[{"award-number":["LGF20H300004"]}],"id":[{"id":"10.13039\/501100017577","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejmech.2023.115258","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T01:54:45Z","timestamp":1678240485000},"page":"115258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases"],"prefix":"10.1016","volume":"251","author":[{"given":"Hualiang","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinde","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianbo","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runpu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyang","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5109-0304","authenticated-orcid":false,"given":"Haopeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115258_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tifs.2021.05.005","article-title":"Protective effects of anthocyanins on neurodegenerative diseases","volume":"117","author":"Li","year":"2021","journal-title":"Trends Food Sci. Technol."},{"key":"10.1016\/j.ejmech.2023.115258_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111253","article-title":"Mechanistic new insights of flavonols on neurodegenerative diseases","volume":"137","author":"Tahir","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2023.115258_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115258_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf9794","article-title":"Kynurenines: tryptophan's metabolites in exercise, inflammation, and mental health","volume":"357","author":"Cervenka","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115258_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev-immunol-032713-120245","article-title":"The aryl hydrocarbon receptor: multitasking in the immune system","volume":"32","author":"Stockinger","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2023.115258_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107746","article-title":"Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets","volume":"221","author":"Dolsak","year":"2021","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115258_bib7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1742-4658.2007.05635.x","article-title":"Tissue expression and biochemical characterization of human 2-amino 3-carboxymuconate 6-semialdehyde decarboxylase, a key enzyme in tryptophan catabolism","volume":"274","author":"Pucci","year":"2007","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2023.115258_bib8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.semcdb.2015.03.002","article-title":"The kynurenine pathway and neurodegenerative disease","volume":"40","author":"Maddison","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2023.115258_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tips.2012.09.006","article-title":"An expanding range of targets for kynurenine metabolites of tryptophan","volume":"34","author":"Stone","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2023.115258_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neuropharm.2016.08.003","article-title":"The kynurenine pathway and the brain: challenges, controversies and promises","volume":"112","author":"Schwarcz","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2023.115258_bib11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neuroscience.2016.05.006","article-title":"Xanthurenic acid is localized in neurons in the central nervous system","volume":"329","author":"Roussel","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2023.115258_bib12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.neuropharm.2016.03.024","article-title":"Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases","volume":"112","author":"Lovelace","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2023.115258_bib13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrn3257","article-title":"Kynurenines in the mammalian brain: when physiology meets pathology","volume":"13","author":"Schwarcz","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115258_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1471-4159.1988.tb04852.x","article-title":"Presence of kynurenic acid in the mammalian brain","volume":"51","author":"Moroni","year":"1988","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2023.115258_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0306-4522(92)90467-G","article-title":"Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse","volume":"51","author":"Saito","year":"1992","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2023.115258_bib16","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1046\/j.1471-4159.1995.65062621.x","article-title":"Metabolism of [5-3H] kynurenine in the rat brain in vivo: evidence for the existence of a functional kynurenine pathway","volume":"65","author":"Guidetti","year":"1995","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2023.115258_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1471-4159.2001.00498.x","article-title":"Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection","volume":"78","author":"Guillemin","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2023.115258_bib18","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","article-title":"Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism","volume":"56","author":"Fukui","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2023.115258_bib19","doi-asserted-by":"crossref","first-page":"22021","DOI":"10.1074\/jbc.M603503200","article-title":"Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35","volume":"281","author":"Wang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib20","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","article-title":"The brain metabolite kynurenic acid inhibits \u03b17 nicotinic receptor activity and increases non-\u03b17 nicotinic receptor expression: physiopathological implications","volume":"21","author":"Hilmas","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115258_bib21","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ntt.2011.07.002","article-title":"On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress","volume":"33","author":"Huitron","year":"2011","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.ejmech.2023.115258_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuropharm.2016.06.020","article-title":"Cinnabarinic acid and xanthurenic acid: two kynurenine metabolites that interact with metabotropic glutamate receptors","volume":"112","author":"Fazio","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2023.115258_bib23","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.bbi.2011.05.005","article-title":"Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients","volume":"25","author":"Myint","year":"2011","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ejmech.2023.115258_bib24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.nbd.2006.07.014","article-title":"Pneumococcal meningitis causes accumulation of neurotoxic kynurenine metabolites in brain regions prone to injury","volume":"24","author":"Bellac","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2023.115258_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neuro.2012.11.007","article-title":"3-Hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system","volume":"34","author":"Gonzalez","year":"2013","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ejmech.2023.115258_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2014.09.034","article-title":"The Janus faces of 3-hydroxykynurenine: dual redox modulatory activity and lack of neurotoxicity in the rat striatum","volume":"1589","author":"Gonzalez","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2023.115258_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.neuint.2006.04.017","article-title":"In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain","volume":"50","author":"Leipnitz","year":"2007","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2023.115258_bib28","doi-asserted-by":"crossref","first-page":"7266","DOI":"10.1021\/bi992997s","article-title":"3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote R-Crystallin cross-linking by metal ion reduction","volume":"39","author":"Goldstein","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.115258_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jorganchem.2015.01.005","article-title":"Iron chelation and redox chemistry of anthranilic acid and 3-hydroxyanthranilic acid: a comparison of two structurally related kynurenine pathway metabolites to obtain improved insights into their potential role in neurological disease development","volume":"782","author":"Chobot","year":"2015","journal-title":"J. Organomet. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF01262727","article-title":"Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice","volume":"42","author":"Lapin","year":"1978","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.ejmech.2023.115258_bib31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0014-2999(81)90587-2","article-title":"Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS","volume":"72","author":"Stone","year":"1981","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115258_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.brainresbull.2021.07.007","article-title":"Caenorhabditis elegans as a model for studies on quinolinic acid-induced NMDAR-dependent glutamatergic disorders","volume":"175","author":"Silveira","year":"2021","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejmech.2023.115258_bib33","first-page":"398","article-title":"Kynurenine pathway and disease: an overview, CNS","volume":"7","author":"Cruz","year":"2007","journal-title":"Neurol. Disord. Dr."},{"key":"10.1016\/j.ejmech.2023.115258_bib34","first-page":"1","article-title":"Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms","volume":"5","author":"Cruz","year":"2012","journal-title":"Int. J. Tryptophan Res."},{"key":"10.1016\/j.ejmech.2023.115258_bib35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/10715760100300391","article-title":"Quinolinic acid -iron(II) complexes: slow autoxidation, but enhanced hydroxyl radical production in the Fenton reaction","volume":"34","author":"Pl\u00e1ten\u00edk","year":"2001","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.ejmech.2023.115258_bib36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12640-009-9051-z","article-title":"Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons","volume":"16","author":"Braidy","year":"2009","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.ejmech.2023.115258_bib37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1471-4159.2003.01857.x","article-title":"Protective effects of the antioxidant selenium on quinolinic acid-induced neurotoxicity in rats: in vitro and in vivo studies","volume":"86","author":"Santamaria","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2023.115258_bib38","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/npp.2014.194","article-title":"Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder","volume":"40","author":"Savitz","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2023.115258_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006344","article-title":"The excitotoxin quinolinic acid induces tau phosphorylation in human neurons","volume":"4","author":"Rahman","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115258_bib40","doi-asserted-by":"crossref","first-page":"P656","DOI":"10.1016\/j.jalz.2012.05.1767","article-title":"P4-065: beta-amyloid production from reactive astrocytes induced by endogenous neurotoxin quinolinic acid: a new aspect of Alzheimer's disease","volume":"8","author":"Okuno","year":"2012","journal-title":"Alzheimers. Dement."},{"key":"10.1016\/j.ejmech.2023.115258_bib41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","article-title":"Ageing as a risk factor for neurodegenerative disease","volume":"15","author":"Hou","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2023.115258_bib42","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clinbiochem.2004.02.007","article-title":"Increasing production of homocysteine and neopterin and degradation of tryptophan with older age","volume":"37","author":"Frick","year":"2004","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejmech.2023.115258_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.mad.2006.01.020","article-title":"Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality","volume":"127","author":"Pertovaara","year":"2006","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.ejmech.2023.115258_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2019.110793","article-title":"Clinical insights into the kynurenine pathway in age-related diseases","volume":"130","author":"Kim","year":"2020","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.ejmech.2023.115258_bib45","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.molmed.2013.02.007","article-title":"Tryptophan metabolism: entering the field of aging and age-related pathologies","volume":"19","author":"van der Goot","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115258_bib46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-3083.2005.01586.x","article-title":"Association of interferon-gamma +874(T\/A) single nucleotide polymorphism with the rate of tryptophan catabolism in healthy individuals","volume":"61","author":"Raitala","year":"2005","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115258_bib47","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1111\/j.1742-4658.2011.08366.x","article-title":"Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats","volume":"278","author":"Braidy","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2023.115258_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2009.05356.x","article-title":"Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism","volume":"1199","author":"Oxenkrug","year":"2010","journal-title":"Ann. NY. Acad. Sci."},{"key":"10.1016\/j.ejmech.2023.115258_bib49","first-page":"474","article-title":"Interferon-gamma-Inducible inflammation: contribution to aging and aging-associated psychiatric disorders","volume":"2","author":"Oxenkrug","year":"2011","journal-title":"Aging. Dis."},{"key":"10.1016\/j.ejmech.2023.115258_bib50","doi-asserted-by":"crossref","first-page":"14912","DOI":"10.1073\/pnas.1203083109","article-title":"Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation","volume":"109","author":"van der Goot","year":"2012","journal-title":"P. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2023.115258_bib51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00702-009-0341-7","article-title":"The extended life span of Drosophila melanogaster eye-color (white and vermilion) mutants with impaired formation of kynurenine","volume":"117","author":"Oxenkrug","year":"2010","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.ejmech.2023.115258_bib52","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/acel.12595","article-title":"Caenorhabditis elegans orthologs of human genes differentially expressed with age are enriched for determinants of longevity","volume":"16","author":"Sutphin","year":"2017","journal-title":"Aging Cell"},{"key":"10.1016\/j.ejmech.2023.115258_bib53","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.aaf2693","article-title":"NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice","volume":"352","author":"Zhang","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115258_bib54","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000086295","article-title":"Age-related increase of kynurenic acid in human cerebrospinal fluid - IgG and beta2-microglobulin changes","volume":"14","author":"Kepplinger","year":"2005","journal-title":"Neurosignals"},{"key":"10.1016\/j.ejmech.2023.115258_bib57","first-page":"289","article-title":"The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease","volume":"47","author":"Armstrong","year":"2009","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.ejmech.2023.115258_bib58","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.cell.2012.02.040","article-title":"Alzheimer mechanisms and therapeutic strategies","volume":"148","author":"Huang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115258_bib59","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2478\/v10039-010-0023-6","article-title":"Kynurenine and its metabolites in Alzheimer's disease patients","volume":"55","author":"Gulaj","year":"2010","journal-title":"Adv. Med. Sci."},{"key":"10.1016\/j.ejmech.2023.115258_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2019.03.015","article-title":"Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-beta and tau","volume":"80","author":"Jacobs","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejmech.2023.115258_bib61","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1471-4159.2009.06175.x","article-title":"Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease","volume":"110","author":"Yamada","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2023.115258_bib62","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ics.2007.07.026","article-title":"Up-regulation of the brain indoleamine 2,3-dioxygenase activity in a mouse model of Alzheimer's disease by systemic endotoxin challenge","volume":"1304","author":"Akimoto","year":"2007","journal-title":"Int. Congr. Ser."},{"key":"10.1016\/j.ejmech.2023.115258_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2020.101800","article-title":"Tryptophan metabolites modify brain Abeta peptide degradation: a role in Alzheimer's disease?","volume":"190","author":"Maitre","year":"2020","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2023.115258_bib64","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neuropharm.2013.02.006","article-title":"The neuroprotector kynurenic acid increases neuronal cell survival through neprilysin induction","volume":"70","author":"Klein","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2023.115258_bib65","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2023.115258_bib66","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/mds.28202","article-title":"Tryptophan metabolites are associated with symptoms and nigral pathology in Parkinson's disease","volume":"35","author":"Heilman","year":"2020","journal-title":"Mov. Disorders"},{"key":"10.1016\/j.ejmech.2023.115258_bib67","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pneurobio.2015.12.009","article-title":"Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease","volume":"155","author":"Lim","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2023.115258_bib68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbr.2007.08.007","article-title":"Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys","volume":"186","author":"Gregoire","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2023.115258_bib69","article-title":"The genetic link between Parkinson's disease and the kynurenine pathway is still missing","volume":"2015","author":"Torok","year":"2015","journal-title":"Parkinsons. Dis."},{"key":"10.1016\/j.ejmech.2023.115258_bib70","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s007020200014","article-title":"Increased neopterin production and tryptophan degradation in advanced Parkinson's disease","volume":"109","author":"Widner","year":"2002","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.ejmech.2023.115258_bib71","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington's disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejmech.2023.115258_bib72","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","article-title":"Tryptophan metabolism and oxidative stress in patients with Huntington's disease","volume":"93","author":"Stoy","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2023.115258_bib73","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","article-title":"Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease","volume":"17","author":"Guidetti","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2023.115258_bib74","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-510X(94)00280-2","article-title":"Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases","volume":"130","author":"Jauch","year":"1995","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejmech.2023.115258_bib75","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1471-4159.1990.tb03143.x","article-title":"Kynurenine pathway measurements in Huntington's disease striaturn: evidence for reduced formation of kynurenic acid","volume":"55","author":"Beal","year":"1990","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2023.115258_bib76","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2006.02.011","article-title":"Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice","volume":"23","author":"Guidetti","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2023.115258_bib77","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/hmg\/ddp527","article-title":"Expression analysis of novel striatal-enriched genes in Huntington disease","volume":"19","author":"Mazarei","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2023.115258_bib78","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","article-title":"Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration","volume":"145","author":"Zwilling","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115258_bib79","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115258_bib80","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/WNR.0b013e32832e34ee","article-title":"Distinct neuroinflammatory profile in post-mortem human Huntington's disease","volume":"20","author":"Silvestroni","year":"2009","journal-title":"Neuroreport"},{"key":"10.1016\/j.ejmech.2023.115258_bib81","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1471-4159.2009.06442.x","article-title":"Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington's disease","volume":"112","author":"Forrest","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2023.115258_bib82","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic Huntington's disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2023.115258_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2012.08.005","article-title":"The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations","volume":"323","author":"Tan","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejmech.2023.115258_bib84","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115258_bib85","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/toxsci\/kfq024","article-title":"Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling","volume":"115","author":"DiNatale","year":"2010","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2023.115258_bib86","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nm.4106","article-title":"Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor","volume":"22","author":"Rothhammer","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115258_bib87","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.tips.2020.11.006","article-title":"Tryptophan metabolism as a pharmacological target","volume":"42","author":"Modoux","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2023.115258_bib88","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41467-017-01725-8","article-title":"Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1","volume":"8","author":"Ballester","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115258_bib89","doi-asserted-by":"crossref","first-page":"8518","DOI":"10.1021\/jacs.8b03691","article-title":"Inhibition mechanisms of human indoleamine 2,3 dioxygenase 1","volume":"140","author":"Ballester","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115258_bib90","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.4049\/jimmunol.0804328","article-title":"The immunoregulatory enzyme Ido paradoxically drives B cell-mediated autoimmunity","volume":"182","author":"Scott","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115258_bib91","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.4049\/jimmunol.1303012","article-title":"Ido2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis","volume":"192","author":"Merlo","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115258_bib92","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1128\/IAI.05659-11","article-title":"Inhibition of indoleamine 2,3-dioxygenase activity by levo-1-methyl tryptophan blocks gamma interferon-induced Chlamydia trachomatis persistence in human epithelial cells","volume":"79","author":"Ibana","year":"2011","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejmech.2023.115258_bib93","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.mp.4002148","article-title":"Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice","volume":"14","author":"O'Connor","year":"2009","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejmech.2023.115258_bib94","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.fct.2007.07.017","article-title":"Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption","volume":"46","author":"Jia","year":"2008","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejmech.2023.115258_bib95","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3233\/JAD-140414","article-title":"The Ido inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease","volume":"43","author":"Yu","year":"2015","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.ejmech.2023.115258_bib96","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1248\/bpb.32.1433","article-title":"Anti-Alzheimer and antioxidant activities of coptidis rhizoma alkaloids","volume":"32","author":"Jung","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2023.115258_bib97","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1073\/pnas.1604453113","article-title":"Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites","volume":"113","author":"Breda","year":"2016","journal-title":"P. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2023.115258_bib98","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/0006-2952(95)00006-L","article-title":"The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat","volume":"49","author":"Salter","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115258_bib99","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/brain\/aww117","article-title":"Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice","volume":"139","author":"Woodling","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2023.115258_bib100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1017\/neu.2019.44","article-title":"Effects of Ido1 and TDO2 inhibition on cognitive deficits and anxiety following LPS-induced neuroinflammation","volume":"32","author":"Imbeault","year":"2020","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.ejmech.2023.115258_bib101","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.bmc.2018.02.014","article-title":"Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (Ido1) inhibition: the design, synthesis of miconazole analogues targeting Alzheimer's disease","volume":"26","author":"Lu","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib102","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2174\/0929867324666170502123114","article-title":"Major developments in the design of inhibitors along the kynurenine pathway","volume":"24","author":"Jacobs","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib103","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00018-009-0166-4","article-title":"Structure, expression, and function of kynurenine aminotransferases in human and rodent brains","volume":"67","author":"Han","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2023.115258_bib104","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/biom10040571","article-title":"Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients","volume":"10","author":"Sanchez","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2023.115258_bib105","doi-asserted-by":"crossref","first-page":"10592","DOI":"10.1523\/JNEUROSCI.1107-14.2014","article-title":"Reduction of brain kynurenic acid improves cognitive function","volume":"34","author":"Kozak","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115258_bib106","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1038\/s41380-019-0401-9","article-title":"Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia","volume":"25","author":"Kindler","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejmech.2023.115258_bib107","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1074\/jbc.M707925200","article-title":"Crystal structure of human kynurenine aminotransferase II, a drug target for the treatment of schizophrenia","volume":"283","author":"Rossi","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib108","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hipo.23040","article-title":"Inhibition of kynurenine aminotransferase II attenuates hippocampus-dependent memory deficit in adult rats treated prenatally with kynurenine","volume":"29","author":"Pocivavsek","year":"2019","journal-title":"Hippocampus"},{"key":"10.1016\/j.ejmech.2023.115258_bib109","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cmdc.200500095","article-title":"Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(Ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor","volume":"1","author":"Pellicciari","year":"2006","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115258_bib110","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neuroscience.2008.11.055","article-title":"Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum","volume":"159","author":"Amori","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2023.115258_bib111","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00702-006-0562-y","article-title":"Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?","volume":"114","author":"Wu","year":"2007","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.ejmech.2023.115258_bib112","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/cmdc.200800109","article-title":"Sequence variants in kynurenine aminotransferase II (KAT II) orthologs determine different potencies of the inhibitor S-ESBA","volume":"3","author":"Pellicciari","year":"2008","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115258_bib113","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/molecules21070856","article-title":"Study of the activity and possible mechanism of action of a reversible inhibitor of recombinant human KAT-2: a promising lead in neurodegenerative and cognitive disorders","volume":"21","author":"Nematollahi","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115258_bib114","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1021\/jm100464k","article-title":"Crystal structure-based selective targeting of the pyridoxal 5'-phosphate dependent enzyme kynurenine aminotransferase II for cognitive enhancement","volume":"53","author":"Rossi","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib115","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1471-4159.2009.05893.x","article-title":"On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo","volume":"109","author":"Amori","year":"2009","journal-title":"J. Neurochem."},{"issue":"Suppl","key":"10.1016\/j.ejmech.2023.115258_bib116","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1093\/schbul\/sbt157","article-title":"Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor","volume":"40","author":"Wu","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ejmech.2023.115258_bib117","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1021\/ml200204m","article-title":"Discovery of brain-penetrant, irreversible kynurenine aminotransferase II Inhibitors for schizophrenia","volume":"3","author":"Dounay","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115258_bib118","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuropharm.2014.03.004","article-title":"A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats","volume":"82","author":"Koshy Cherian","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2023.115258_bib119","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1021\/ml300237v","article-title":"Structure-based design of irreversible human KAT II inhibitors: discovery of new potency-enhancing interactions","volume":"4","author":"Tuttle","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115258_bib120","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bmcl.2013.02.039","article-title":"PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency","volume":"23","author":"Dounay","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115258_bib121","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1039\/C2MD20166F","article-title":"Discovery of hydroxamate bioisosteres as KAT II inhibitors with improved oral bioavailability and pharmacokinetics","volume":"4","author":"Henderson","year":"2013","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2023.115258_bib122","unstructured":"M. Okuyama, K. Fukunaga, K. Usui, N. Hayashi, D. Iijima, H. Horiuchi, N. Itagaki, Novel Bicyclic or Tricyclic Heterocyclic Compounds, WO2015163339A1."},{"key":"10.1016\/j.ejmech.2023.115258_bib123","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.gene.2005.09.034","article-title":"Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family","volume":"365","author":"Yu","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2023.115258_bib124","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.bmcl.2011.12.138","article-title":"Design and synthesis of novel inhibitors of human kynurenine aminotransferase-I","volume":"22","author":"Akladios","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115258_bib125","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1021\/jm9000874","article-title":"Structural insight into the inhibition of human kynurenine aminotransferase I\/glutamine transaminase K","volume":"52","author":"Han","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib126","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1021\/jm501350y","article-title":"Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease","volume":"58","author":"Sherman","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib127","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/jm00031a015","article-title":"Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase","volume":"37","author":"Pellicciari","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib128","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/S0960-894X(98)00517-4","article-title":"4-Phenyl-4-oxo-butanoic acid derivatives inhibitors of kynurenine 3-hydroxylase","volume":"8","author":"Cfiordani","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115258_bib129","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0014-2999(96)00613-9","article-title":"(R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats","volume":"315","author":"Speciale","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115258_bib130","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/978-1-4615-0135-0_71","article-title":"Modulation of the kynurine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine-3-hydroxylase","volume":"527","author":"Pellicciari","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2023.115258_bib131","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/jnr.21183","article-title":"Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications","volume":"85","author":"Borroni","year":"2007","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejmech.2023.115258_bib132","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.expneurol.2005.07.004","article-title":"Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease","volume":"197","author":"Sapko","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2023.115258_bib133","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature12039","article-title":"Structural basis of kynurenine 3-monooxygenase inhibition","volume":"496","author":"Amaral","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115258_bib134","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1021\/jm970467t","article-title":"Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase","volume":"40","author":"R\u00f6ver","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib135","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1046\/j.1471-4159.2002.01090.x","article-title":"Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures","volume":"82","author":"Carpenedo","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2023.115258_bib136","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1124\/dmd.112.046532","article-title":"Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048","volume":"40","author":"Beconi","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2023.115258_bib137","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1021\/jm4009295","article-title":"Foundation-directed therapeutic development in Huntington's disease","volume":"57","author":"Dominguez","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib138","series-title":"Optimization of Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington's Disease","author":"Sherman","year":"2013"},{"key":"10.1016\/j.ejmech.2023.115258_bib139","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.expneurol.2016.05.005","article-title":"The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease","volume":"282","author":"Beaumont","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2023.115258_bib140","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.4020","article-title":"Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis","volume":"22","author":"Mole","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115258_bib141","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15827","article-title":"Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase","volume":"8","author":"Hutchinson","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115258_bib142","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.chembiol.2018.01.008","article-title":"Structural basis for inhibitor-induced hydrogen peroxide production by kynurenine 3-Monooxygenase","volume":"25","author":"Kim","year":"2018","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115258_bib143","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1021\/acsomega.7b02091","article-title":"Diclofenac identified as a kynurenine 3-monooxygenase binder and inhibitor by molecular similarity techniques","volume":"3","author":"Shave","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2023.115258_bib144","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0014-827X(99)00009-9","article-title":"Pyrrolo[3,2-c]quinoline derivatives: a new class of kynurenine-3-hydroxylase inhibitors, Il","volume":"54","author":"Heidempergher","year":"1999","journal-title":"Farmaco"},{"key":"10.1016\/j.ejmech.2023.115258_bib145","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.bmcl.2012.04.002","article-title":"Ianthellamide A, a selective kynurenine-3-hydroxylase inhibitor from the Australian marine sponge Ianthella quadrangulata","volume":"22","author":"Feng","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115258_bib146","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1177\/1087057113518069","article-title":"Lead discovery for human kynurenine 3-monooxygenase by high-throughput RapidFire mass spectrometry","volume":"19","author":"Lowe","year":"2014","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.ejmech.2023.115258_bib147","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaci.2015.09.055","article-title":"The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases","volume":"137","author":"Harden","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115258_bib148","doi-asserted-by":"crossref","first-page":"6700","DOI":"10.1111\/jcmm.14547","article-title":"A novel role of kynureninase in the growth control of breast cancer cells and its relationships with breast cancer","volume":"23","author":"Liu","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115258_bib149","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1021\/ja00019a039","article-title":"Stereochemistry and mechanism of aldol reactions catalyzed by kynureninase","volume":"113","author":"Phillips","year":"1991","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115258_bib150","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/ja00057a007","article-title":"S-Aryl-L-cysteine S,S-dioxides: design, synthesis, and evaluation of a new class of inhibitors of kynureninase","volume":"115","author":"Dua","year":"1993","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115258_bib151","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0960-894X(97)10209-8","article-title":"S-Aryl cysteine S,S-dioxides as inhibitors of mammalian kynureninase","volume":"8","author":"Drysdale","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115258_bib152","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0960-894X(01)00758-2","article-title":"2-Amino-4-[3-hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase","volume":"12","author":"Walsh","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115258_bib153","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1046\/j.1432-1033.2002.02854.x","article-title":"Purification and biochemical characterization of some of the properties of recombinant human kynureninase","volume":"269","author":"Walsh","year":"2002","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2023.115258_bib154","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1158\/0008-5472.CAN-12-3831","article-title":"The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress","volume":"73","author":"Sahm","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115258_bib155","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.envres.2019.02.034","article-title":"High phthalate exposure increased urinary concentrations of quinolinic acid, implicated in the pathogenesis of neurological disorders: is this a potential missing link?","volume":"172","author":"Nassan","year":"2019","journal-title":"Environ. Res."},{"key":"10.1016\/j.ejmech.2023.115258_bib156","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4137\/IJTR.S7052","article-title":"Effects of kynurenine pathway inhibition on NAD metabolism and cell viability in human primary astrocytes and neurons","volume":"4","author":"Braidy","year":"2011","journal-title":"Int. J. Tryptophan Res."},{"key":"10.1016\/j.ejmech.2023.115258_bib157","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41586-018-0645-6","article-title":"De novo NAD(+) synthesis enhances mitochondrial function and improves health","volume":"563","author":"Katsyuba","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115258_bib158","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1021\/acs.jmedchem.7b01254","article-title":"alpha-Amino-beta-carboxymuconate-epsilon-semialdehyde Decarboxylase (ACMSD) Inhibitors as novel modulators of de novo nicotinamide adenine dinucleotide (NAD(+)) biosynthesis","volume":"61","author":"Pellicciari","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib159","doi-asserted-by":"crossref","first-page":"e865","DOI":"10.1038\/tp.2016.133","article-title":"An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation","volume":"6","author":"Brundin","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejmech.2023.115258_bib160","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa1616361","article-title":"NAD deficiency, congenital malformations, and niacin supplementation","volume":"377","author":"Shi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115258_bib161","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s002210100887","article-title":"Immunohistochemical visualization of newly formed quinolinate in the normal and excitotoxically lesioned rat striatum","volume":"141","author":"Lehrmann","year":"2001","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.ejmech.2023.115258_bib162","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1089\/neu.2006.23.866","article-title":"4-chloro-3-hydroxyanthranilate reduces local quinolinic acid synthesis, improves functional recovery, and preserves white matter after spinal cord injury","volume":"23","author":"Yates","year":"2006","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.ejmech.2023.115258_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111842","article-title":"Targeting aryl hydrocarbon receptor for next-generation immunotherapies: selective modulators (SAhRMs) versus rapidly metabolized ligands (RMAhRLs)","volume":"185","author":"Dolciami","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib164","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.phrs.2014.10.009","article-title":"Tranilast: a review of its therapeutic applications","volume":"91","author":"Darakhshan","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2023.115258_bib165","doi-asserted-by":"crossref","first-page":"E6145","DOI":"10.1073\/pnas.1607843113","article-title":"Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor","volume":"113","author":"Kaye","year":"2016","journal-title":"P. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2023.115258_bib166","doi-asserted-by":"crossref","first-page":"20768","DOI":"10.1073\/pnas.1009201107","article-title":"An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis","volume":"107","author":"Quintana","year":"2010","journal-title":"P. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2023.115258_bib167","article-title":"Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115258_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108055","article-title":"Recent advances in clinical trials targeting the kynurenine pathway","volume":"236","author":"Pires","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115258_bib169","doi-asserted-by":"crossref","first-page":"9421","DOI":"10.1021\/acs.jmedchem.5b00326","article-title":"Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (Ido1) inhibitors","volume":"58","author":"R\u00f6hrig","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115258_bib170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17060946","article-title":"Kynurenine aminotransferase isozyme inhibitors: a review","volume":"17","author":"Nematollahi","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115258_bib171","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1021\/bi8010434","article-title":"Kynurenine 3-monooxygenase from pseudomonas fluorescens: substrate-like inhibitors both stimulate flavin reduction and stabilize the flavin-peroxo intermediate yet result in the production of hydrogen peroxide","volume":"47","author":"Reabe","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.115258_bib172","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejps.2010.05.003","article-title":"Strategy for effective brain drug delivery","volume":"40","author":"Alam","year":"2010","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2023.115258_bib173","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/0023210-200923010-00003","article-title":"Getting into the brain: approaches to enhance brain drug delivery","volume":"23","author":"Patel","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2023.115258_bib174","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s42003-019-0520-5","article-title":"A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites","volume":"2","author":"Zhang","year":"2019","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2023.115258_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108702","article-title":"Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases","volume":"697","author":"Zhang","year":"2021","journal-title":"Arch. Biochem. Biophys."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:52:33Z","timestamp":1778676753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423002246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":173,"alternative-id":["S0223523423002246"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115258","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115258"}}